FDA clears ResMed's OSA (obstructive sleep apnoea) product platform:
This article was originally published in Clinica
Executive Summary
ResMed has received US FDA 510(k) clearance to market its S7 Elite CPAP and AutoSet Spirit autotitrating devices for treating obstructive sleep apnoea (OSA). Both systems offer fully integrated heated humidification options and use system hardware common to both units, allowing accessories to be added or interchanged between models and ultimately streamlining inventory management, says the San Diego, California firm. The integrated devices are smaller and quieter than ResMed's current product line.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.